Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2016 Jan;95(4):e2600.
doi: 10.1097/MD.0000000000002600.

Large HDL Subfraction But Not HDL-C Is Closely Linked With Risk Factors, Coronary Severity and Outcomes in a Cohort of Nontreated Patients With Stable Coronary Artery Disease: A Prospective Observational Study

Affiliations
Observational Study

Large HDL Subfraction But Not HDL-C Is Closely Linked With Risk Factors, Coronary Severity and Outcomes in a Cohort of Nontreated Patients With Stable Coronary Artery Disease: A Prospective Observational Study

Jian-Jun Li et al. Medicine (Baltimore). 2016 Jan.

Abstract

High-density lipoprotein (HDL) is highly heterogeneous in its size and composition. Till now, the link of HDL subfractions to coronary risk is less clear. We aimed to investigate the associations of HDL subfractions with traditional risk factors (RFs), coronary severity, and outcomes in a cohort of nontreated patients with stable coronary artery disease (CAD). We prospectively enrolled 591 eligible patients. Baseline HDL subfractions were separated by Lipoprint system. HDL subfractions (large, medium, and small) and HDL-cholesterol (HDL-C) levels were dichotomized into low and high group according to the 50 percentile. Coronary severity was evaluated by SYNTAX, Gensini, and Jeopardy scoring systems. Patients were followed up annually for major adverse cardiovascular events (MACEs). Cox proportional hazards' models were used to evaluate the risk of HDL subfractions on MACEs. Patients with high large HDL-C levels had a decreased number of RFs. Significantly, large HDL-C levels were negatively associated with coronary severity assessed by SYNTAX and Gensini score (both P < 0.05). New MACEs occurred in 67 (11.6%) patients during a median 17.0 months follow-up. Moreover, the log-rank test revealed that there was a significant difference between high and low large HDL-C groups in event-free survival analysis (P = 0.013), but no differences were observed in total HDL-C groups and medium or small HDL-C groups (both P > 0.05). In particular, the multivariate Cox-proportional hazards model revealed that high large HDL-C was associated with lower MACEs risk (hazard ratio [95% confidence interval] 0.531 [0.295-0.959]) independent of potential confounders. Higher large HDL-C but not medium, small, or total HDL-C is associated with lower cardiovascular risk, highlighting the potential beneficial of HDL subfractionation.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Number of risk factors in high and low groups of HDL-C, large HDL-C, medium HDL-C, and small HDL-C. HDL-C = high-density lipoprotein cholesterol.
FIGURE 2
FIGURE 2
Relationship of HDL subfractions and future cardiovascular events based on the number of risk factors tertiles. HDL = high-density lipoprotein.
FIGURE 3
FIGURE 3
Cumulative event-free survival analysis between high and low groups of HDL-C (A), large HDL-C (B), medium HDL-C (C), and small HDL-C (D). HDL-C = high-density lipoprotein cholesterol.
FIGURE 4
FIGURE 4
Univariate (A) and multivariate (B) Cox proportional models to reveal the associations of HDL-C, large HDL-C, medium HDL-C, and small HDL-C with future cardiovascular events. HDL-C = high-density lipoprotein cholesterol.

References

    1. Blacher J, Evans A, Arveiler D, et al. Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study. J Hum Hypertens 2010; 24:19–26. - PubMed
    1. Baigent C, Blackwell L, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670–1681. - PMC - PubMed
    1. Keys A. Alpha lipoprotein (HDL) cholesterol in the serum and the risk of coronary heart disease and death. Lancet 1980; 2:603–606. - PubMed
    1. Tuteja S, Rader DJ. High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm. Clin Pharmacol Ther 2014; 96:48–56. - PubMed
    1. Fazio S, Linton MF. Elevated high-density lipoprotein (HDL) levels due to hepatic lipase mutations do not reduce cardiovascular disease risk: another strike against the HDL dogma. J Clin Endocrinol Metab 2009; 94:1081–1083. - PMC - PubMed

Publication types